# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
RBC Capital analyst Kennen MacKay maintains Nuvation Bio (NYSE:NUVB) with a Outperform and raises the price target from $4 t...
Key Takeaways: Cancer treatment maker ProfoundBio announced it will be purchased by Denmark’s Genmab for $1.8 billion The d...
U.S. stock futures were lower this morning, with the Nasdaq futures falling by around 0.2% on Wednesday.
HC Wainwright & Co. analyst Robert Burns maintains Nuvation Bio (NYSE:NUVB) with a Buy and raises the price target from ...
Shares of LuxUrban Hotels Inc. (NASDAQ: LUXH) fell sharply during Wednesday’s session after the company issued preliminary fo...
U.S. stocks were higher, with the Dow Jones index gaining around 300 points on Wednesday.